Related Experiment Video
Updated: Apr 1, 2026

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway
Daisuke Fujimoto1, Yuki Ueda1, Yasuo Hirono1
1First Department of Surgery, Faculty of Medicine, University of Fukui, Fukui, Japan.
Abstract:
The Hippo pathway significantly correlates with organ size control and tumorigenesis. The activity of YAP/TAZ, a transducer of the Hippo pathway, is required to sustain self-renewal and tumor-initiation capacities in cancer stem cells (CSCs). But, upstream signals that control the mammalian Hippo pathway have not been well understood. Here, we reveal a connection between the Protease-activated receptor 1 (PAR1) signaling pathway and the Hippo-YAP pathway in gastric cancer stem-like cells. The selective PAR1 agonist TFLLR-NH2 induces an increase in the fraction of side population cells which is enriched in CSCs, and promotes tumorigenesis, multi cancer drug resistance, cell morphological change, and cell invasion which are characteristics of CSCs. In addition, PAR1 activation inhibits the Hippo-YAP pathway kinase Lats via Rho GTPase. Lats kinase inhibition in turn results in increased nuclear localization of dephosphorylated YAP. Furthermore, PAR1 activation confers CSCs related traits via the Hippo-YAP pathway, and the Hippo-YAP pathway correlates with epithelial mesenchymal transition which is induced by PAR1 activation. Our research suggests that the PAR1 signaling deeply participates in the ability of multi drug resistance and tumorigenesis through interactions with the Hippo-YAP pathway signaling in gastric cancer stem-like cells. We presume that inhibited YAP is a new therapeutic target in the treatment human gastric cancer invasion and metastasis by dysregulated PAR1 or its agonists.
Insights
Protease-activated receptor 1 (PAR1) signaling activates gastric cancer stem cells by inhibiting the Hippo-YAP pathway. This promotes tumor growth and drug resistance, suggesting YAP as a therapeutic target.
Area of Science:
- Oncology
- Cell Biology
- Molecular Signaling
Background:
- The Hippo pathway regulates organ size and is implicated in tumorigenesis.
- Yeast Andematopoeisis/Transcriptional Activator (YAP)/Tazor (TAZ) are key Hippo pathway transducers essential for cancer stem cell (CSC) self-renewal and tumor initiation.
- Upstream regulators of the mammalian Hippo pathway remain largely uncharacterized.
Purpose of the Study:
- To investigate the link between Protease-activated receptor 1 (PAR1) signaling and the Hippo-YAP pathway in gastric cancer stem-like cells.
- To elucidate the mechanisms by which PAR1 influences CSC characteristics and tumorigenesis.
Main Methods:
- Utilized a selective PAR1 agonist (TFLLR-NH2) to activate PAR1 signaling in gastric cancer stem-like cells.
- Assessed changes in side population cell fraction, tumorigenesis, drug resistance, cell morphology, invasion, and epithelial-mesenchymal transition (EMT).
- Investigated the impact of PAR1 activation on the Hippo-YAP pathway, including Lats kinase activity and YAP nuclear localization, via Rho GTPase.
Main Results:
- PAR1 activation increased the proportion of CSC-enriched side population cells, promoting tumorigenesis, multi-drug resistance, invasion, and morphological changes.
- PAR1 activation inhibited Lats kinase activity through Rho GTPase, leading to increased nuclear YAP localization.
- PAR1 signaling conferred CSC traits via the Hippo-YAP pathway and correlated with PAR1-induced EMT.
Conclusions:
- PAR1 signaling plays a critical role in gastric cancer stem-like cell drug resistance and tumorigenesis through interaction with the Hippo-YAP pathway.
- PAR1 activation promotes CSC characteristics and EMT in gastric cancer.
- Inhibited YAP represents a potential therapeutic target for gastric cancer invasion and metastasis driven by dysregulated PAR1 signaling.
More Related Videos
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Hedgehog Signaling Pathway